In the years running up to the deal the companies' laboratories had failed to come up with new drugs to replace the household names―Augmentin (antibiotic), Paxil (antidepressant) and Flixonase (in-tranasal anti-inflammatory)―nearing the end of their patents. Little known to the outside ...